Surg-09. agents for fluorescence guided glioma surgery: review of preclinical and clinical results
CONCLUSION:For FGS in glioma surgery, 5-ALA and fluorescein offer the best improvement in GTR rate and survival. However, several pre-clinically tested agents may be interesting future alternatives. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Senders, J., Muskens, I., Schnoor, R., Karhade, A., Cote, D., Smith, T., Broekman, M. Tags: SURGICAL THERAPY Source Type: research
Surg-08. awake-awake-awake craniotomies in glioma surgery
CONCLUSIONS:Dexmedetomidine provides excellent setting for fully awake surgeries. Our experience shows that using dexmedetomidine as sole anaesthetic drug during awake craniotomies sedates moderately, acts anxiolytic and after ceasing infusion enables quick and reliable clinical neurological assessment of patients. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Schipmann, S., Müller, I., Suero, E. J., Maas, M., Schwake, M., Ewelt, C., Stummer, W. Tags: SURGICAL THERAPY Source Type: research
Surg-07. endonasal endoscopic excision of orbital lesions
CONCLUSIONS:Endoscopic approaches to orbital lesions are minimally invasive and bear excellent outcome. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Jaiswal, A., Kesri, A., Mehrotra, A., Das, K., Jaiswal, S., Behari, S. Tags: SURGICAL THERAPY Source Type: research
Surg-06. outcomes of second surgery for recurrent glioblastoma multiforme: a retrospective case control study
CONCLUSION:Second surgery for recurrent GBM is beneficial with a survival advantage. There is also a survival advantage in having chemotherapy (with or without surgery) at recurrence. Outcomes post surgery was also promising. More studies are required in the era of improved surgical techniques and new anti-neoplastic therapies. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Wann, A., Tully, P., Barnes, L., Lwin, Z., Jeffree, L., Drummond, K., Gan, H., Khasraw, M. Tags: SURGICAL THERAPY Source Type: research
Surg-05. national trends for reoperation in patients with glioblastoma multiforme
CONCLUSION:Though definitive conclusions cannot be made given the lack of granularity, our study does support gross total resection as the initial treatment of choice for GBM, followed by reoperation, if tolerated, at the time of recurrence. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Chen, Y.-R., Sole, J., Ugiliweneza, B., Boakye, M., Skirboll, S. Tags: SURGICAL THERAPY Source Type: research
Surg-04. differences between intraoperative mri flair and t2 tumor volumes compared to postoperative corresponding volumes in glioma surgery
CONCLUSIONS:Postoperative FLAIR and T2 signal volumes are significantly higher than intraoperatively obtained corresponding volumes for all gliomas studied. Further work will be required but this study questions the validity of T2 and FLAIR images obtained intraoperatively. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Jensen, R. Tags: SURGICAL THERAPY Source Type: research
SURG-03. RESECTION OF HIGHLY LANGUAGE-ELOQUENT BRAIN LESIONS PURELY BASED ON rTMS LANGUAGE MAPPING WITHOUT AWAKE SURGERY
CONCLUSION:The present study shows for the first time the feasibility of successfully resecting language-eloquent brain lesions purely based on the results of negative language maps provided by rTMS language mapping and rTMS-based DTI-FT. In very select cases this technique might provide a rescue strategy with an optimal functional and oncological outcome when awake surgery is not feasible. Yet, any final statement will need more patients to be enrolled. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Ille, S., Sollmann, N., Ringel, F., Meyer, B., Krieg, S. M. Tags: SURGICAL THERAPY Source Type: research
Surg-02. uk low grade glioma management - a survey of national practice
CONCLUSIONS:A large proportion of respondents confirmed that they provide specialist LGG services in established multidisciplinary environments. The majority of centres do recognise the value of upfront surgery with the aim of achieving significant bulk resection. The methodology surrounding awake craniotomy varies markedly across the UK centres. A unit-to-unit variation in the post-operative care of LGG patients was also noted, with disparity in which patients are referred for adjuvant therapy. This survey supports the establishment of a UK National LGG Working Group who can setup a regular National outcome audit &am...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Shastin, D. Tags: SURGICAL THERAPY Source Type: research
STMC-39. PRECISION FUNCTIONAL GENOMICS FOR GLIOBLASTOMA: IDENTIFYING MOLECULAR THERAPEUTIC TARGETS USING CRISPR-Cas9 AND RNAi TECHNOLOGIES DIRECTLY IN TUMOR ISOLATES
Glioblastoma (GBM) is the most aggressive and common form of adult brain cancer and is among the deadliest cancers, with a median survival of 15 months using standard-of-care therapies. Thus, improved treatments for GBM are desperately needed. To identify new GBM molecular therapeutic targets, our group has performed multiple functional genetic screens in patient-derived GBM stem-like cells (GSCs) and non-transformed human neural stem and progenitor cells (NPCs), which represent non-neoplastic controls. These screens, using both RNAi and CRISPR-Cas9 platforms, have led to the identification of several key molecular vu...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Hoellerbauer, P., Feldman, H. Tags: STEM CELLS Source Type: research
Stmc-38. eya1 identified by in vitro and in vivo phage display biopanning demonstrates role in glioblastoma stem cell proliferation through oncogene interaction
Glioblastoma stem cells (GSC) comprise of a subpopulation of tumor cells that possess the unique ability to self renew and facilitate tumor growth. Further characterization of these cells will help to understand the unique mechanisms that drive these cells, which will lead to the development of more advanced therapeutic strategies at effectively and specifically targeting these cells. In order to identify novel target proteins that may play a critical role in the maintenance of glioma stem cells, we have employed two separate phage display biopanning strategies to isolate novel 7 amino acid peptides sequences that display ...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Huang, P., Wu, Q., Rich, J., Liu, J. Tags: STEM CELLS Source Type: research
Stmc-37. s100a4 is a critical regulator of stemness and the mesenchymal phenotype in gbms
Accumulating evidence indicates that cellular stresses such as chemotherapy, radiation treatment, or hypoxic and acidic microenvironments can either select for or induce cellular changes that confer GBM cells with more stem cell-like or mesenchymal phenotypes. The mesenchymal phenotype is associated with aggressiveness and tumor recurrence in GBMs and stemness in other tumors. In addition, hypoxia and acidosis have been shown to increase the number of tumor initiating cells (TICs) in human GBM cultures, suggesting that elucidating mechanisms that regulate stemness and mesenchymal transition is critical for improving GBM tr...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Chow, K.-h., Park, H. J., George, J., Gallup, A., Wood, S., Yamamoto, K., Neilson, E., Graber, J., Steindler, D., Yun, K. Tags: STEM CELLS Source Type: research
Stmc-36. cd109 regulates tumor propagation of radio-resistant glioma stem cells
In this study we discovered CD109 as a novel tumor initiation marker for the MES subtype of glioma stem cells. Here we report that exposure of glioma stem-like cells (GSCs) to ionizing radiation (IR) promotes a persistent transcriptomic and phenotypic shift toward a MES subtype in a CD109-dependent manner. We observed that in both de novo and IR-induced MES GSCs, CD109+, but not CD109- populations are highly clonogenic in vitro and radio-resistant and tumorigenic in vivo. In addition, inhibition of CD109 through shRNAs attenuates clonogenicity, tumor propagation and radio-resistance and dramatically inhibits YAP/TAZ signal...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Audia, A., Minata, M., Guo, X., Mukheef, F., Patel, H., Ezhilarasan, R., Sulman, E., Nakano, I., Bhat, K. Tags: STEM CELLS Source Type: research
STMC-35. DIVERGENT Wnt SIGNALING REGULATES GLIOMA STEM CELLS AND TUMOR PHENOTYPE
Glioblastomas (GBMs), the most aggressive adult brain tumor, can be classified into clinically relevant subtypes based on gene expression and genomic alterations that influence survival and treatment response. Additionally, glioma stem cells (GSCs) are recognized as unique subpopulations that contribute to tumorigenesis, recurrence, and therapy resistance. Because Wnt signaling is critical in neural stem cell growth, we hypothesized the Wnt pathway would regulate GSCs and glioma subtypes. We have characterized two distinct subtypes of GSCs, proneural (PN) and mesenchymal (MES), by gene expression profiling, in vitro growth...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Alvarez, A., Huang, T., Pangeni, R., Lu, S., Brennan, C., Sulman, E., Lu, X., Nakano, I., Zhang, W., Zhang, Z., Hu, B., Cheng, S.-Y. Tags: STEM CELLS Source Type: research
Stmc-34. role of interleukin-8/cxcr2 regulated epigenetic plasticity in gbm recurrence
Emerging evidence has revealed the enrichment of cancer stem cells (CSCs) in glioblastoma (GBM) and other cancers post-therapy. This can occur by dedifferentiation of non-CSCs to CSCs within the tumor population, which may be responsible for promoting the therapeutic resistance. To elucidate the molecular mechanisms of post-therapy cellular plasticity, a gene expression analysis, comparing the pre- and the post-therapy GBM CSCs (GSCs), revealed that Interleukin-8 (IL-8) transcripts are significantly elevated in post-therapy CD133+ GSCs. IL-8 is a pro-inflammatory chemokine that is upregulated both at mRNA and protein level...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Hasan, T., Atashi, F., Kim, J., Guo, D., Park, C., Wu, M., Dey, M., Lesniak, M., Horbinski, C., Ahmed, A. Tags: STEM CELLS Source Type: research
Stmc-33. differential migration pathways of therapeutic stem cell carriers to glioma after intranasal delivery
Neural stem cells (NSCs) and mesenchymal stem cells (MSCs) possess natural tropism to brain tumors. The unique stem cell intranasal delivery strategy bypasses the blood brain barrier and was recently demonstrated to convey therapeutic benefits in xenograft mouse models in conjunction with radiation and oncolytic virotherapy. It is imperative to understand the tumor tropism of therapeutic stem cells delivered intranasally to formulate optimal therapeutic strategies. To overcome the limitations of in vivo tracing of small number of stem cells delivered intranasally, we leveraged our mesoporous nanoparticle (MSN)-based radiol...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Yu, D., Bonamici, N., Tsai, H.-M., Cheng, S.-H., Wu, M., Pituch, K., Han, Y., Chen, C.-T., Lesniak, M., Balyasnikova, I. Tags: STEM CELLS Source Type: research
